Track topics on Twitter Track topics that are important to you
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
The post Breakthrough Therapy Designation granted to treatment for IDLs appeared first on European Pharmaceutical Review.
Original Article: Breakthrough Therapy Designation granted to treatment for IDLsNEXT ARTICLE
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...